Literature DB >> 12667576

Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.

Daniel Soffer1, Issam Moussa, Murat Karatepe, Kishore J Harjai, Judith Boura, Simon R Dixon, Cindy L Grines, William W O'Neill, Gary S Roubin, Jeffrey W Moses.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12667576     DOI： 10.1016/s0002-9149(03)00024-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  2 in total

1.  Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.

Authors:  J W van Werkum; W B M Gerritsen; J C Kelder; C M Hackeng; S M Ernst; V H M Deneer; M J Suttorp; B J W M Rensing; H W M Plokker; J M Ten Berg
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

2.  Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

Authors:  Walter J Janse van Rensburg; Jan P Roodt; Seb Lamprecht; S Muriel Meiring; Philip N Badenhorst
Journal:  Clin Exp Med       Date:  2012-01-05       Impact factor: 3.984
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.